Xylem (XYL) Stock Forecast, Price Target & Predictions
XYL Stock Forecast
Xylem stock forecast is as follows: an average price target of $141.83 (represents a 16.04% upside from XYL’s last price of $122.23) and a rating consensus of 'Buy', based on 14 wall street analysts offering a 1-year stock forecast.
XYL Price Target
The average price target for Xylem (XYL) is $141.83 based on 1-year price targets from 14 Wall Street analysts in the past 3 months, with a price target range of $170.00 to $107.00. This represents a potential 16.04% upside from XYL's last price of $122.23.
XYL Analyst Ratings
According to 14 Wall Street analysts, Xylem's rating consensus is 'Buy'. The analyst rating breakdown for XYL stock is 0 'Strong Buy' (0.00%), 8 'Buy' (57.14%), 5 'Hold' (35.71%), 1 'Sell' (7.14%), and 0 'Strong Sell' (0.00%).
Xylem Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 13, 2024 | Damian Karas | UBS | $165.00 | $127.50 | 29.41% | 34.99% |
| Jul 31, 2024 | Michael Halloran | Robert W. Baird | $170.00 | $133.48 | 27.36% | 39.08% |
| May 31, 2024 | Bryan Blair | Oppenheimer | $152.00 | $139.40 | 9.04% | 24.36% |
| May 29, 2024 | John Eade | Argus Research | $165.00 | $140.36 | 17.55% | 34.99% |
| May 03, 2024 | Brett Linzey | Mizuho Securities | $135.00 | $135.99 | -0.73% | 10.45% |
| May 03, 2024 | Deane Dray | RBC Capital | $162.00 | $135.99 | 19.13% | 32.54% |
| May 03, 2024 | Michael Halloran | Robert W. Baird | $155.00 | $135.99 | 13.98% | 26.81% |
| Apr 08, 2024 | Brad Hewitt | Wolfe Research | $143.00 | $128.27 | 11.48% | 16.99% |
| Apr 04, 2024 | Deane Dray | RBC Capital | $153.00 | $127.25 | 20.24% | 25.17% |
| Aug 18, 2023 | Nathan Jones | Stifel Nicolaus | $133.00 | $99.80 | 33.27% | 8.81% |
The latest Xylem stock forecast, released on Aug 13, 2024 by Damian Karas from UBS, set a price target of $165.00, which represents a 29.41% increase from the stock price at the time of the forecast ($127.50), and a 34.99% increase from XYL last price ($122.23).
Xylem Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 9 |
| Avg Price Target | - | - | $155.56 |
| Last Closing Price | $122.23 | $122.23 | $122.23 |
| Upside/Downside | -100.00% | -100.00% | 27.27% |
In the current month, the average price target of Xylem stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Xylem's last price of $122.23. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Nov 06, 2024 | Cowen & Co. | Hold | Hold | Hold |
| Sep 03, 2024 | Cowen & Co. | Buy | Hold | Downgrade |
| Aug 13, 2024 | UBS | - | Buy | Initialise |
| Jun 05, 2024 | Cowen & Co. | Buy | Buy | Hold |
| May 31, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| May 28, 2024 | RBC Capital | Outperform | Outperform | Hold |
| May 03, 2024 | RBC Capital | Outperform | Outperform | Hold |
| Apr 08, 2024 | Citigroup | Neutral | Neutral | Hold |
| Apr 08, 2024 | Wolfe Research | Outperform | Outperform | Hold |
| Apr 04, 2024 | RBC Capital | Outperform | Outperform | Hold |
Xylem's last stock rating was published by Cowen & Co. on Nov 06, 2024. The company gave XYL a "Hold" rating, the same as its previous rate.
Xylem Financial Forecast
Xylem Revenue Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $2.12B | - | $1.72B | $1.45B | $1.51B | $1.38B | $1.36B | $1.27B | $1.32B | $1.26B | $1.35B | $1.26B | $1.37B | $1.22B |
| Avg Forecast | $2.51B | $2.40B | $2.47B | $2.32B | $2.43B | $2.33B | $2.39B | $2.22B | $2.32B | $2.23B | $2.26B | $2.11B | $2.18B | $2.17B | $2.14B | $2.00B | $2.05B | $1.99B | $1.49B | $1.35B | $1.41B | $1.34B | $1.32B | $1.24B | $1.31B | $1.29B | $1.31B | $1.17B | $1.29B | $1.16B |
| High Forecast | $2.53B | $2.42B | $2.50B | $2.34B | $2.45B | $2.36B | $2.41B | $2.24B | $2.34B | $2.25B | $2.28B | $2.12B | $2.19B | $2.17B | $2.14B | $2.00B | $2.07B | $2.04B | $1.50B | $1.36B | $1.43B | $1.34B | $1.32B | $1.24B | $1.31B | $1.29B | $1.31B | $1.17B | $1.29B | $1.16B |
| Low Forecast | $2.48B | $2.37B | $2.45B | $2.30B | $2.40B | $2.31B | $2.36B | $2.20B | $2.29B | $2.21B | $2.24B | $2.09B | $2.16B | $2.17B | $2.14B | $2.00B | $2.03B | $1.93B | $1.47B | $1.33B | $1.40B | $1.34B | $1.32B | $1.24B | $1.31B | $1.29B | $1.31B | $1.17B | $1.29B | $1.16B |
| # Analysts | 5 | 4 | 5 | 4 | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 8 | 12 | 6 | 3 | 3 | 6 | 13 | 6 | 6 | 5 | 5 | 5 | 11 | 12 | 11 | 10 | 9 | 9 | 9 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.03% | - | 1.16% | 1.08% | 1.07% | 1.03% | 1.04% | 1.03% | 1.01% | 0.98% | 1.03% | 1.07% | 1.06% | 1.05% |
Xylem's average Quarter revenue forecast for Mar 24 based on 3 analysts is $2.00B, with a low forecast of $2.00B, and a high forecast of $2.00B. XYL's average Quarter revenue forecast represents a -5.76% decrease compared to the company's last Quarter revenue of $2.12B (Dec 23).
Xylem EBITDA Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 4 | 5 | 4 | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 8 | 12 | 6 | 3 | 3 | 6 | 13 | 6 | 6 | 5 | 5 | 5 | 11 | 12 | 11 | 10 | 9 | 9 | 9 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $266.00M | $152.00M | $246.00M | $203.00M | $269.00M | $102.00M | $215.00M | $168.00M | $198.00M | $216.00M | $221.00M | $197.00M | $241.00M | $135.00M |
| Avg Forecast | $404.55M | $387.16M | $399.31M | $374.30M | $391.59M | $376.91M | $385.23M | $359.01M | $373.93M | $360.28M | $364.50M | $340.90M | $352.72M | $350.28M | $346.19M | $148.17M | $331.51M | $321.25M | $240.18M | $134.70M | $210.66M | $211.97M | $208.04M | $122.45M | $207.29M | $203.92M | $207.76M | $114.05M | $204.18M | $183.32M |
| High Forecast | $408.39M | $390.84M | $403.10M | $377.85M | $395.30M | $380.48M | $388.89M | $362.41M | $377.48M | $363.70M | $367.96M | $342.52M | $354.33M | $350.83M | $346.19M | $177.80M | $334.75M | $329.33M | $242.46M | $161.64M | $252.79M | $211.97M | $208.04M | $146.94M | $207.29M | $203.92M | $207.76M | $136.86M | $204.18M | $183.32M |
| Low Forecast | $400.63M | $383.41M | $395.44M | $370.67M | $387.79M | $373.25M | $381.50M | $355.53M | $370.31M | $356.79M | $360.97M | $337.65M | $349.49M | $349.74M | $346.19M | $118.53M | $328.28M | $311.87M | $237.85M | $107.76M | $168.53M | $211.97M | $208.04M | $97.96M | $207.29M | $203.92M | $207.76M | $91.24M | $204.18M | $183.32M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.80% | 0.47% | 1.02% | 1.51% | 1.28% | 0.48% | 1.03% | 1.37% | 0.96% | 1.06% | 1.06% | 1.73% | 1.18% | 0.74% |
3 analysts predict XYL's average Quarter EBITDA for Mar 24 to be $148.17M, with a high of $177.80M and a low of $118.53M. This is -44.30% lower than Xylem's previous annual EBITDA (Dec 23) of $266.00M.
Xylem Net Income Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 4 | 5 | 4 | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 8 | 12 | 6 | 3 | 3 | 6 | 13 | 6 | 6 | 5 | 5 | 5 | 11 | 12 | 11 | 10 | 9 | 9 | 9 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $266.00M | $152.00M | $92.00M | $99.00M | $149.00M | $12.00M | $112.00M | $82.00M | $113.00M | $114.00M | $113.00M | $87.00M | $148.00M | $37.00M |
| Avg Forecast | $363.46M | $349.39M | $351.07M | $300.81M | $347.13M | $334.08M | $326.17M | $277.11M | $315.08M | $298.43M | $290.86M | $248.44M | $275.35M | $270.37M | $256.37M | $87.41M | $232.90M | $215.95M | $198.93M | $79.46M | $120.22M | $160.65M | $130.92M | $72.24M | $149.40M | $144.12M | $152.36M | $50.37M | $167.33M | $123.16M |
| High Forecast | $367.94M | $353.70M | $355.40M | $304.52M | $351.41M | $338.20M | $330.19M | $280.52M | $318.97M | $302.10M | $294.45M | $258.28M | $277.78M | $270.51M | $256.40M | $104.89M | $242.60M | $223.22M | $201.38M | $95.35M | $144.27M | $160.65M | $130.92M | $86.69M | $149.40M | $144.12M | $152.36M | $60.44M | $167.33M | $123.16M |
| Low Forecast | $358.88M | $344.99M | $346.65M | $297.02M | $342.76M | $329.87M | $322.06M | $273.61M | $311.11M | $294.66M | $287.20M | $238.60M | $272.91M | $270.22M | $256.34M | $69.93M | $223.19M | $208.67M | $196.42M | $63.57M | $96.18M | $160.65M | $130.92M | $57.79M | $149.40M | $144.12M | $152.36M | $40.29M | $167.33M | $123.16M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.14% | 0.70% | 0.46% | 1.25% | 1.24% | 0.07% | 0.86% | 1.14% | 0.76% | 0.79% | 0.74% | 1.73% | 0.88% | 0.30% |
Xylem's average Quarter net income forecast for Mar 24 is $87.41M, with a range of $69.93M to $104.89M. XYL's average Quarter net income forecast represents a -67.14% decrease compared to the company's last Quarter net income of $266.00M (Dec 23).
Xylem SG&A Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 4 | 5 | 4 | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 8 | 12 | 6 | 3 | 3 | 6 | 13 | 6 | 6 | 5 | 5 | 5 | 11 | 12 | 11 | 10 | 9 | 9 | 9 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $446.00M | $354.00M | $315.00M | $294.00M | $314.00M | $304.00M | $301.00M | $273.00M | $304.00M | $301.00M | $292.00M | $266.00M |
| Avg Forecast | $572.74M | $548.13M | $565.32M | $529.92M | $554.39M | $533.60M | $545.39M | $508.26M | $529.39M | $510.07M | $516.04M | $482.63M | $499.36M | $495.91M | $490.12M | $324.05M | $469.34M | $454.81M | $340.03M | $294.59M | $320.24M | $306.36M | $300.69M | $267.81M | $299.61M | $294.73M | $300.28M | $174.26M | $295.10M | $264.96M |
| High Forecast | $578.17M | $553.32M | $570.68M | $534.94M | $559.65M | $538.66M | $550.56M | $513.08M | $534.41M | $514.90M | $520.94M | $484.92M | $501.64M | $496.69M | $490.12M | $388.86M | $473.91M | $466.25M | $343.26M | $353.51M | $384.29M | $306.36M | $300.69M | $321.37M | $299.61M | $294.73M | $300.28M | $209.12M | $295.10M | $264.96M |
| Low Forecast | $567.19M | $542.81M | $559.84M | $524.78M | $549.02M | $528.43M | $540.10M | $503.34M | $524.26M | $505.12M | $511.04M | $478.03M | $494.80M | $495.14M | $490.12M | $259.24M | $464.76M | $441.52M | $336.73M | $235.67M | $256.20M | $306.36M | $300.69M | $214.25M | $299.61M | $294.73M | $300.28M | $139.41M | $295.10M | $264.96M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.31% | 1.20% | 0.98% | 0.96% | 1.04% | 1.14% | 1.00% | 0.93% | 1.01% | 1.73% | 0.99% | 1.00% |
Xylem's average Quarter SG&A projection for Sep 23 is $454.81M, based on 13 Wall Street analysts, with a range of $441.52M to $466.25M. The forecast indicates a 1.98% rise compared to XYL last annual SG&A of $446.00M (Jun 23).
Xylem EPS Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 4 | 5 | 4 | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 8 | 12 | 6 | 3 | 3 | 6 | 13 | 6 | 6 | 5 | 5 | 5 | 11 | 12 | 11 | 10 | 9 | 9 | 9 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $1.10 | - | $0.45 | $0.55 | $0.83 | $0.07 | $0.62 | $0.45 | $0.63 | $0.63 | $0.63 | $0.49 | $0.82 | $0.20 |
| Avg Forecast | $1.49 | $1.43 | $1.44 | $1.23 | $1.42 | $1.37 | $1.34 | $1.14 | $1.29 | $1.22 | $1.19 | $1.02 | $1.13 | $1.11 | $1.05 | $0.84 | $0.96 | $0.89 | $0.82 | $0.62 | $0.79 | $0.66 | $0.54 | $0.41 | $0.61 | $0.59 | $0.63 | $0.38 | $0.69 | $0.51 |
| High Forecast | $1.51 | $1.45 | $1.46 | $1.25 | $1.44 | $1.39 | $1.35 | $1.15 | $1.31 | $1.24 | $1.21 | $1.06 | $1.14 | $1.11 | $1.05 | $0.84 | $1.00 | $0.92 | $0.83 | $0.63 | $0.80 | $0.66 | $0.54 | $0.41 | $0.61 | $0.59 | $0.63 | $0.38 | $0.69 | $0.51 |
| Low Forecast | $1.47 | $1.42 | $1.42 | $1.22 | $1.41 | $1.35 | $1.32 | $1.12 | $1.28 | $1.21 | $1.18 | $0.98 | $1.12 | $1.11 | $1.05 | $0.84 | $0.92 | $0.86 | $0.81 | $0.61 | $0.78 | $0.66 | $0.54 | $0.41 | $0.61 | $0.59 | $0.63 | $0.38 | $0.69 | $0.51 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.15% | 0.00% | 0.55% | 0.89% | 1.05% | 0.11% | 1.15% | 1.09% | 1.03% | 1.06% | 1.01% | 1.31% | 1.19% | 0.40% |
According to 3 Wall Street analysts, Xylem's projected average Quarter EPS for Mar 24 is $0.84, with a low estimate of $0.84 and a high estimate of $0.84. This represents a -23.77% decrease compared to XYL previous annual EPS of $1.10 (Dec 23).
Xylem Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| AOS | A. O. Smith | $71.41 | $86.50 | 21.13% | Buy |
| XYL | Xylem | $122.23 | $141.83 | 16.04% | Buy |
| IEX | IDEX | $223.61 | $237.44 | 6.18% | Buy |
| FELE | Franklin Electric | $105.34 | $103.00 | -2.22% | Buy |
| DOV | Dover | $198.73 | $190.07 | -4.36% | Buy |
| EMR | Emerson Electric | $129.56 | $120.33 | -7.12% | Buy |
| PNR | Pentair | $104.75 | $95.88 | -8.47% | Buy |
| ITT | ITT | $153.00 | $132.60 | -13.33% | Buy |
| ITW | Illinois Tool Works | $266.46 | $230.92 | -13.34% | Hold |
| FLS | Flowserve | $60.08 | $51.00 | -15.11% | Buy |
| PH | Parker-Hannifin | $689.76 | $546.07 | -20.83% | Buy |
| IR | Ingersoll Rand | $102.38 | $70.67 | -30.97% | Buy |
| ETN | Eaton | $363.69 | $243.05 | -33.17% | Buy |